All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How should we manage HMA failure?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Valeria Santini, University of Florence, Florence, IT. We asked, How should we manage hypomethylating agent (HMA) failure?

How should we manage HMA failure?

Santini firstly discusses when to assess HMA failure in patients with MDS. She then provides an overview of new agents for de novo, high-risk MDS. This includes a new HMA (guadecitabine), a BCL2 inhibitor (venetoclax), and immunotherapy (magrolimab and sabatolimab). She also evaluates targeting agents (ivosidenib and enasidenib) for relapsed/refractory MDS. Santini finishes by discussing APR-246, a new agent for patients with TP53 mutations, who have the worst prognosis.